Hepatitis B virus (HBV) infection is one of the major risk factors in the development of hepatocullular carcinoma (HCC) worldwide. The therapy for HBV-related hepatocellular carcinoma (HCC) remains a major challenge in medicine considering the low response rate (usually below 10％) to current chemotherapy and the high relapsing rate (up to or beyond 50％) after surgery (1). Whether antivirals or interferon therapy for chronic HBV infection will offer a reduction or prevention of HCC development remains to be clarified (2). There are several reasons to explain the difficulty or failure to treat HCC. One reason may lie in the inherent nature of the liver which is the organ responsible for the metabolism of chemicals and drugs. The second reason is the heterogenecity of HCCs and complex mechanisms of HBV tumorigenesis which make the choice of therapies difficult (3). Although current advances in cancer genomics have tried to identify the potential HCC biomarkers and molecular classification of HCC is proposed (4), their application to clinical therapy remains to be verified.